Crizotinib resistance: implications for therapeutic strategies - Annals of Oncology
Crizotinib Shows Promise for Childhood Cancers - NCI
Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC) — ALK POSITIVE
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer | NEJM
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) | Molecular Cancer | Full Text
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - Lung Cancer
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models | Nature Communications
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression | BMC Cancer | Full Text
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial - Journal of Thoracic Oncology
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls - ScienceDirect
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
Timeline for crizotinib development. Abbreviations: ALK1, ALK-positive;... | Download Scientific Diagram
Alectinib Replaces Crizotinib Drug as Potential Therapy for Advanced Lung Cancer
Main adverse events with crizotinib in clinical trials | Download Table
Crizotinib - Wikipedia
Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data | Future Oncology
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial - Journal of Thoracic Oncology
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) - Lung Cancer
Ensartinib Tops Crizotinib in ALK-Positive NSCLC | MedPage Today
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial - Journal of Thoracic Oncology
